Hematologic Neoplasms
Information
- Disease name
- Hematologic Neoplasms
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03680092 | Active, not recruiting | Phase 2 | Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | November 26, 2019 | December 2027 |
| NCT02477878 | Active, not recruiting | Phase 1 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | July 2016 | January 2033 |
| NCT00038376 | Completed | Phase 2 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | May 8, 1990 | June 30, 2005 |
| NCT00044759 | Completed | Phase 3 | Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma | January 2003 | |
| NCT00051311 | Completed | Phase 2 | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | January 3, 2003 | September 25, 2014 |
| NCT00067730 | Completed | Phase 4 | A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation | March 2003 | October 2003 |
| NCT00312429 | Completed | Phase 1/Phase 2 | Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | January 2002 | May 2008 |
| NCT00389428 | Completed | Phase 1 | Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. | September 2006 | December 2009 |
| NCT00421213 | Completed | Phase 2 | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | December 2006 | April 2012 |
| NCT00473577 | Completed | Phase 1 | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients | August 2005 | December 2007 |
| NCT00526045 | Completed | Phase 1/Phase 2 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients | July 2007 | April 2012 |
| NCT00595686 | Completed | Phase 1 | Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies | January 2008 | May 2010 |
| NCT00618969 | Completed | Phase 2 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | February 2008 | February 2016 |
| NCT00623870 | Completed | Phase 1 | A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. | May 2008 | November 2012 |
| NCT01021683 | Completed | The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants | July 2009 | July 2010 | |
| NCT00028418 | Completed | Phase 1 | Clofarabine in Chronic Lymphocytic Leukemia | February 1999 | March 2004 |
| NCT00900614 | Completed | Phase 1 | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer | May 2009 | October 2010 |
| NCT00914849 | Completed | Phase 2 | Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies | August 2009 | February 2012 |
| NCT00987987 | Completed | Phase 1/Phase 2 | Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion | December 2005 | December 2009 |
| NCT00997386 | Completed | Phase 2 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | September 2009 | January 2016 |
| NCT00001748 | Completed | Phase 1 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | June 1998 | May 2000 |
| NCT01244906 | Completed | Phase 2 | Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | December 2010 | December 2014 |
| NCT01275534 | Completed | Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation | November 2010 | November 2012 | |
| NCT01362179 | Completed | National Marrow Donor Program Long-Term Donor Follow-Up | October 2010 | October 15, 2020 | |
| NCT01790568 | Completed | Phase 2 | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant | December 2014 | October 31, 2017 |
| NCT01802879 | Completed | Phase 2 | Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | June 24, 2013 | November 19, 2018 |
| NCT01869218 | Completed | Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy | April 2, 2013 | January 15, 2021 | |
| NCT01915498 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | August 27, 2013 | October 31, 2023 |
| NCT02033928 | Completed | Comprehensive Frailty Assessment | April 2014 | August 2017 | |
| NCT02061761 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies | March 13, 2014 | February 16, 2022 |
| NCT02193880 | Completed | N/A | Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) | October 9, 2014 | March 13, 2018 |
| NCT02329847 | Completed | Phase 1/Phase 2 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | March 11, 2015 | February 9, 2022 |
| NCT02367196 | Completed | Phase 1 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | March 12, 2015 | December 24, 2020 |
| NCT02504047 | Completed | N/A | Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units | February 2014 | February 2019 |
| NCT02623309 | Completed | Phase 3 | Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients | February 23, 2016 | March 12, 2021 |
| NCT02635984 | Completed | Phase 3 | Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens | November 2015 | December 2017 |
| NCT02650791 | Completed | Phase 3 | Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study | October 2016 | December 2019 |
| NCT02745743 | Completed | Phase 1 | Phase I Trial of BAY1251152 for Advanced Blood Cancers | June 17, 2016 | August 3, 2018 |
| NCT03087227 | Completed | N/A | Shared Health Information System for Febrile Neutropenia | February 22, 2017 | October 20, 2019 |
| NCT03136445 | Completed | Phase 3 | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia | June 2015 | June 18, 2022 |
| NCT03219268 | Completed | Phase 1 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | August 18, 2017 | February 8, 2023 |
| NCT03349372 | Completed | Impact of Pulmonary Follow-up After Stem Cell Graft | November 1, 2016 | October 31, 2017 | |
| NCT03403075 | Completed | N/A | Therapeutic Education in Physical Activity (ETAF) | January 1, 2018 | December 3, 2019 |
| NCT03483194 | Completed | Phase 2/Phase 3 | Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) | September 6, 2018 | June 19, 2020 |
| NCT03575767 | Completed | Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT | May 8, 2018 | September 30, 2018 | |
| NCT04264767 | Completed | Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA | April 17, 2019 | January 30, 2021 | |
| NCT04303091 | Completed | N/A | The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients | March 2, 2018 | December 20, 2018 |
| NCT04760184 | Completed | Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden | April 1, 2021 | December 31, 2021 | |
| NCT05061095 | Completed | Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey | March 21, 2022 | September 26, 2023 | |
| NCT05054231 | Not yet recruiting | N/A | Immunological Profile for Patients Treated With CAR-T Cells | October 5, 2021 | October 5, 2026 |
| NCT05672420 | Not yet recruiting | Phase 1/Phase 2 | Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies | January 1, 2023 | January 31, 2025 |
| NCT03094026 | Recruiting | N/A | Cognitive Training Intervention and Attitudes Towards Genetics | August 21, 2017 | July 2025 |
| NCT05716113 | Recruiting | Early Phase 1 | CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL | February 15, 2023 | May 20, 2025 |
| NCT03301493 | Recruiting | Genomic Testing and Resulting Medical Decisions | March 30, 2017 | December 2024 | |
| NCT03023202 | Recruiting | UWCCC Molecular Tumor Board Registry | March 30, 2016 | March 2027 | |
| NCT05602051 | Recruiting | N/A | Mindfulness-based Virtual Reality Intervention | November 1, 2021 | December 1, 2022 |
| NCT03505086 | Recruiting | Bleeding In Thrombocytopenia Explained | December 4, 2018 | June 1, 2026 | |
| NCT05902845 | Recruiting | Early Phase 1 | RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL | April 30, 2023 | April 30, 2025 |
| NCT00071045 | Recruiting | Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | October 8, 2003 | ||
| NCT03735992 | Recruiting | N/A | Mind-body Medicine for Patients With Malignant Hematological Diseases | September 6, 2017 | December 31, 2024 |
| NCT03983850 | Recruiting | Phase 1/Phase 2 | Optimizing PTCy Dose and Timing | July 9, 2019 | May 29, 2026 |
| NCT05907603 | Recruiting | Early Phase 1 | Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) | March 8, 2023 | March 8, 2025 |
| NCT01374841 | Recruiting | Phase 2 | Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors | August 2010 | December 2023 |
| NCT06339541 | Recruiting | The ACC Preclinical Research Platform for Precision Oncology | June 5, 2023 | December 1, 2024 | |
| NCT04310592 | Recruiting | Phase 1 | Natural Killer Cell (CYNK-001) Infusions in Adults With AML | March 12, 2020 | December 3, 2024 |
| NCT04448184 | Recruiting | Phase 3 | Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) | February 16, 2022 | February 2027 |
| NCT04691284 | Recruiting | N/A | Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation | March 1, 2021 | December 2024 |
| NCT06422533 | Recruiting | N/A | Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients | November 7, 2023 | August 30, 2025 |
| NCT04959175 | Recruiting | Phase 1/Phase 2 | Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | September 23, 2021 | April 30, 2027 |
| NCT06433349 | Recruiting | A Multi-center Investigation of Family Health. | May 13, 2024 | December 31, 2025 | |
| NCT05256537 | Recruiting | Phase 2 | Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil | April 26, 2022 | September 30, 2024 |
| NCT05327023 | Recruiting | Phase 1/Phase 2 | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | May 23, 2022 | July 2, 2029 |
| NCT05549232 | Recruiting | Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital | August 24, 2022 | March 31, 2024 | |
| NCT02958462 | Recruiting | N/A | Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | January 16, 2017 | September 15, 2035 |
| NCT05819762 | Recruiting | Evaluation of ClearLLab LS Screening Panel | May 25, 2023 | September 30, 2024 | |
| NCT05882175 | Recruiting | Prospective Validation of the OHI Index | March 3, 2021 | March 3, 2026 | |
| NCT05895994 | Recruiting | Early Phase 1 | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | March 10, 2023 | February 20, 2026 |
| NCT03722186 | Suspended | Phase 1 | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies | November 13, 2018 | October 2021 |
| NCT02900248 | Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice | October 2, 2017 | March 29, 2019 | |
| NCT03648372 | Terminated | Phase 1/Phase 2 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | October 1, 2018 | December 18, 2023 |
| NCT02895529 | Terminated | Phase 4 | A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy | November 30, 2016 | May 2, 2018 |
| NCT00957580 | Terminated | Phase 2 | Trial of Pimasertib in Hematological Malignancies | September 30, 2009 | December 31, 2012 |
| NCT00698685 | Terminated | Phase 2 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | January 23, 2006 | April 26, 2011 |
| NCT03083327 | Unknown status | N/A | Prophylactic Early PN in HPT/BMT | November 23, 2017 | May 1, 2022 |
| NCT01488591 | Unknown status | Biomarker Research for Personalized Medicine | April 2009 | ||
| NCT03288441 | Unknown status | Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia | March 20, 2018 | December 31, 2021 | |
| NCT04323605 | Unknown status | N/A | Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant | January 2021 | February 2022 |
| NCT00750126 | Unknown status | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation | April 2007 | April 2009 |
| NCT03320915 | Unknown status | Phase 2 | Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT | October 1, 2017 | December 2019 |
| NCT03743480 | Unknown status | N/A | Early Palliative Care and Hematological Cancer Patients | November 21, 2018 | November 2020 |
| NCT03908138 | Unknown status | Phase 4 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | March 30, 2019 | December 31, 2022 |
| NCT02944045 | Unknown status | Phase 3 | Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients | February 15, 2017 | October 2022 |
| NCT01332006 | Unknown status | Phase 2 | Intra-bone Cord Blood Transplantation | November 2009 | December 2019 |
| NCT04871165 | Unknown status | Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals | March 24, 2021 | March 1, 2024 | |
| NCT04275154 | Withdrawn | Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy | September 2020 | May 25, 2021 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D019337